LENZ Therapeutics (NASDAQ:LENZ - Free Report) had its target price upped by Citigroup from $44.00 to $47.00 in a research report report published on Thursday morning,Benzinga reports. They currently have a buy rating on the stock.
Separately, TD Cowen began coverage on shares of LENZ Therapeutics in a report on Tuesday, March 18th. They issued a "buy" rating and a $60.00 target price on the stock. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $41.67.
Read Our Latest Report on LENZ
LENZ Therapeutics Price Performance
Shares of NASDAQ LENZ traded up $0.59 during mid-day trading on Thursday, hitting $27.08. 93,541 shares of the stock traded hands, compared to its average volume of 166,292. The company has a market cap of $744.73 million, a PE ratio of -5.67 and a beta of 0.58. LENZ Therapeutics has a twelve month low of $14.42 and a twelve month high of $38.93. The firm has a 50 day simple moving average of $24.15 and a two-hundred day simple moving average of $27.08.
LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) last issued its earnings results on Wednesday, March 19th. The company reported ($0.46) EPS for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.04). On average, equities research analysts anticipate that LENZ Therapeutics will post -2.18 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently added to or reduced their stakes in LENZ. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of LENZ Therapeutics in the 4th quarter worth approximately $29,000. KLP Kapitalforvaltning AS bought a new position in LENZ Therapeutics in the 4th quarter valued at $46,000. Tower Research Capital LLC TRC increased its position in shares of LENZ Therapeutics by 162.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,860 shares of the company's stock valued at $54,000 after purchasing an additional 1,151 shares during the last quarter. Virtus ETF Advisers LLC purchased a new stake in shares of LENZ Therapeutics during the 4th quarter valued at $67,000. Finally, SG Americas Securities LLC raised its stake in shares of LENZ Therapeutics by 20.7% during the 4th quarter. SG Americas Securities LLC now owns 5,458 shares of the company's stock worth $158,000 after purchasing an additional 935 shares during the period. 54.32% of the stock is currently owned by hedge funds and other institutional investors.
About LENZ Therapeutics
(
Get Free Report)
LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
Recommended Stories
Before you consider LENZ Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LENZ Therapeutics wasn't on the list.
While LENZ Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
